Inactive Instrument

Harpoon Therapeutics, Inc.

HARP

US41358P2056

Biotechnology & Medical Research

Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from S&P TMI Index

March 10, 2024

Latest news about Harpoon Therapeutics, Inc.

Global markets live: Domino's Pizza, Generali, Oracle, Intel, Boeing...	Mar. 12
Wall Street: start of the week down before CPI	Mar. 11	CF
Merck Completes Acquisition of Harpoon Therapeutics	Mar. 11	MT
Merck: acquisition of Harpoon Therapeutics finalized	Mar. 11	CF
Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from NASDAQ Composite Index	Mar. 10	CI
Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc..	Mar. 10	CI
Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from S&P TMI Index	Mar. 10	CI
North American Morning Briefing : Stock Futures -2-	Feb. 27	DJ
Citigroup Downgrades Harpoon Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $13	Feb. 26	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	Jan. 23	DJ
Arix Bioscience eyes USD19 million return from Harpoon sale	Jan. 19	AN
Arix Bioscience Flags Proceeds from Merck's Purchase of Harpoon Therapeutics	Jan. 19	MT
North American Morning Briefing : Central Bankers -2-	Jan. 17	DJ
North American Morning Briefing : Samsung Warning -2-	Jan. 09	DJ
Arix Bioscience's Portfolio Company Signs $680 Million Takeover Deal with Merck & Co.	Jan. 08	MT
Merck Agrees to Buy Harpoon Therapeutics in $680 Million Deal	Jan. 08	MT
Trending : Johnson & Johnson and Merck & Co. Announce Acquisitions	Jan. 08	DJ
Canaccord Genuity Downgrades Harpoon Therapeutics to Hold From Buy, Cuts Price Target to $23 From $30	Jan. 08	MT
HC Wainwright Downgrades Harpoon Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $12	Jan. 08	MT
Top Midday Gainers	Jan. 08	MT
News Highlights : Top Company News of the Day - Monday at 1 PM ET	Jan. 08	DJ
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
News Highlights : Top Company News of the Day - Monday at 11 AM ET	Jan. 08	DJ
Investors lower their expectations	Jan. 08
Drugmakers kick off industry conference with two cancer deals	Jan. 08	RE

Chart Harpoon Therapeutics, Inc.

Duration

Period

More charts

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company's TriTAC product candidates include HPN217, and HPN328. The Company's ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-10.09%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs